THE ROLE OF GENOMIC SCREENING IN TRANSFORMING PUBLIC HEALTH Understanding ethical, legal & social impacts of genomic screening
With
Dr Jane Tiller, Ethical, Legal & Social Adviser,
Public Health Genomics, Monash University
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | July 2025
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
Jane also focusses on identifying and addressing the ethical, legal and social barriers to public acceptability and uptake of genetic screening. She co-founded the Australian Genetic Non-Discrimination Working Group, and led a project from 2020-2023 about genetic discrimination in life insurance. Jane led significant advocacy efforts towards translating her research findings into real world policy change. She was instrumental in the Government’s 2024 announcement that it will legislate a total ban on the use of genetic results in life insurance underwriting. Jane’s work has been recognised through a number of competitive awards, including recently the prestigious 2024 Research Australia Advocacy Award.
Source: Supplied
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
-
Medical research institutes association responds to draft national research strategy
On 27 August 2025, the Minister for Health, Disability and Ageing announced the release of the draft National Health and Medical Research Strategy (the National Strategy).
Involved in the initial consultation phase, was the Association of Australian Medical Research Institutes (AAMRI), the peak body for medical research institutes across Australia. Member institutes work on a broad spectrum of human health issues such as preventive health, chronic disease, mental health, immunology and Indigenous health. Their research ranges from fundamental biomedical discovery through to clinical research and the translation of research findings.
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
